• Supports addition of new Early-Career Investigators (ECIs) to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
• ECIs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• Requires Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding.
• Designated Mentor not required to be at the same institution as the ECI.
• Preliminary data required.
• Clinical trials allowed.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $725,000 for direct costs (plus indirect costs).
• Maximum period of performance 4 years.

• Supports expansion of a consortium that will facilitate rapid execution of collaborative Phase II or Phase I/II clinical trials to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease impact of kidney cancer.
• Funds may not be used for research or development of clinical protocols.
• Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.
• Up to two (2) Clinical Trial Sites will be selected and be jointly responsible for proposing, selecting, and conducting trials within the existing Kidney Cancer Research Consortium.
• Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $600,000 for direct costs (plus indirect costs).
• Maximum period of performance 3 years.

• Prepares nurses for active careers in collaborative clinical kidney cancer research and patient care.
• Requires participation of a mentor with extensive experience in kidney cancer clinical research.
• Emphasis placed on structured, interdisciplinary clinical research training environment.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $300,000 for direct costs (plus indirect costs).
• Maximum period of performance 2 years.

• Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.
• Emphasis on innovation.
• Funding for clinical trials not allowed.
• Preliminary data not allowed.
• Blinded review.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $100,000 for direct costs (plus indirect costs).
• Maximum period of performance 1 year.

Early Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline.

• Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
• Preliminary data required.
• Innovation and Impact are the most important review criteria.
• Funding for clinical trials not allowed.
• FY20 KCRP Areas of Emphasis strongly encouraged (see Areas of Emphasis listed above).
• Different funding options, based on the scope of research. It is the responsibility of the PI to select the funding option that is most appropriate for the research proposed. 
• Early Detection Option: Supports basic or preclinical research that focuses on biomarkers, improved imaging capabilities, and/or new technologies that may foster new paradigms for the early detection of kidney cancer. With justification, applications under the early detection option may request a higher level of funding within the defined period of performance. Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.
• Epidemiology Option: Supports preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the kidney cancer field. With compelling justification, epidemiology option studies may request higher levels of funding within the defined period of performance. Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.
• Submission of a Letter of Intent is required prior to full application submission.

• Maximum funding of $600,000 in direct costs (plus indirect costs).
• Maximum period of performance 3 years.

Early Detection Option:

• Maximum funding of $650,000 in direct costs (plus indirect costs).
• Maximum period of performance 3 years.

Epidemiology Option:

• Maximum funding of $2 million in direct costs (plus indirect costs).
• Maximum period of performance 3 years.

• Must possess a doctoral and/or medical degree (or equivalent).
• Have 3 years or less of postdoctoral and/or mentored clinical research training experience (excluding family medical leave).
• All other academic ranks are ineligible.

• Supports research opportunities focused on kidney cancer for individual in the early stages of their careers.
• Requires participation of a designated mentor who is an experienced kidney cancer researcher.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $195,000 for direct costs (plus indirect costs).
• Maximum period of performance 3 years.

• Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.
• Supports translational correlative studies.
• Preliminary data required.
• Funding for clinical trials not allowed.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance 3 years.